We determined IC50 values for vincristine, paclitaxel and Alisertib/MLN8237, an Aurora kinase A inhibitor in clinical trials for neuroblastoma [24], [32] and then combined the drugs in six combinational equipotent ratios based on the IC50 values in order to assess effects on proliferation and obtain combination indices (CI) by the method of Chou and Talaly [33]. This evidence concerns the gene AURKA and neuroblastoma.